Is Retatrutide FDA Approved? Status, Phase 3 and Filing Timeline

Is retatrutide FDA approved? Not as of September 2026. Lilly plans to file in Q1 2027 after positive Phase 3 results. Here is what that means and what is unresolved.

Signal IQ Editorial4 min read · Updated Nov 8, 2026
Is Retatrutide FDA Approved? Status, Phase 3 and Filing Timeline
In this article
  1. Is retatrutide FDA approved yet?
  2. Why did the filing move to Q1 2027?
  3. Retatrutide Phase 3 results: what has been reported
  4. Is retatrutide a GLP-1 or a GLP-3?
  5. Why is Lilly calling it a BLA?
  6. Is retatrutide safe?
  7. Is retatrutide available?
  8. What to watch next
  9. Frequently asked questions
  10. References

Is retatrutide FDA approved? No. As of September 2026 it is still an investigational drug, and Eli Lilly says it intends to send its U.S. application to FDA in the first quarter of 2027. Good Phase 3 results are not an approval, and no approved retatrutide product exists.

Key takeaways
  • Retatrutide is not FDA approved (status as of September 2026); Lilly’s planned filing is Q1 2027.
  • The later date reflects unfinished manufacturing documentation (CMC), not a failed trial.
  • Lilly’s July 23, 2026 announcement said TRIUMPH-2 and TRIUMPH-3 reached their main goals.
  • A filing target is only a plan; FDA still has to accept, assess and rule on the application.
  • Vials sold online under the name are not the studied medicine, and some have held other drugs.

Is retatrutide FDA approved yet?

Not yet. Earlier expectations pointed to a 2026 submission, and Lilly now aims for Q1 2027. After a submission, FDA must first judge that the application is complete enough to file, then assess the evidence, inspect facilities and negotiate labeling before deciding. None of that begins until the submission is made and accepted.

Why did the filing move to Q1 2027?

Lilly said it is still finishing its Chemistry, Manufacturing, and Controls (CMC) package, which documents how the product is produced and kept under control. For a peptide medicine it typically spans:

  • what the substance is, how pure it is, and limits on impurities;
  • each manufacturing step and the checks on it;
  • whether batches match across lots and sites;
  • how long the product stays stable on the shelf;
  • whether the container or injection device is compatible;
  • the lab methods that release each batch, and how supply will scale.

FDA assesses what patients will actually receive, not only the molecule used in trials. Clinical results and manufacturing readiness are two halves of one application.

Retatrutide Phase 3 results: what has been reported

Retatrutide is an investigational medicine given once a week that acts on GIP, GLP-1 and glucagon receptors. Lilly has announced several TRIUMPH Phase 3 readouts:

TrialPopulationReported
TRIUMPH-4Obesity and knee osteoarthritisResults announced Dec 11, 2025
TRIUMPH-12,339 adults with overweight or obesity, no diabetes; 80 weeksResults announced May 21, 2026
TRIUMPH-2Overweight or obesity with type 2 diabetesPrimary endpoint reached after 80 weeks (topline, July 23, 2026)
TRIUMPH-3Severe obesity with established cardiovascular diseasePrimary endpoint reached after 80 weeks (topline, July 23, 2026)

A topline release says only whether a headline goal was reached. Full publications are still needed for adverse-event tables, who dropped out and why, results by dose and subgroup analyses. For tolerability by dose, see retatrutide side effects.

Is retatrutide a GLP-1 or a GLP-3?

It is better called a triple agonist, since it hits GLP-1, GIP and glucagon receptors. “GLP-3” is an informal nickname, not an official drug class. Comparisons with other drugs appear in semaglutide vs tirzepatide vs retatrutide and how retatrutide works.

Why is Lilly calling it a BLA?

Lilly has said it plans to file a Biologics License Application. In the source material, Lilly and FDA are described as disagreeing over whether retatrutide counts as a biological product or as a drug that would go through a New Drug Application. The answer shapes the filing route, any exclusivity and the timetable, and it is a question separate from the CMC work and the trial data.

Is retatrutide safe?

Safety has only been studied in trials of Lilly’s manufactured drug at set doses. The commonest effects were digestive, and dysesthesia (an odd skin sensation) was reported more at higher doses. Long-term data and post-approval monitoring do not exist yet, and nothing from trials can be applied to a product of unknown content.

Is retatrutide available?

Not as an approved medicine. FDA has said retatrutide cannot lawfully be compounded. Compounding cannot make an unapproved research material into the drug studied in TRIUMPH, and neither a label nor a seller’s certificate can confirm identity, sterility, impurities, strength or storage history.

Note: In September 2026, Australia’s TGA tested a vial sold as retatrutide after a patient was hospitalized. It held no retatrutide; it contained semaglutide not shown on the label, at roughly eight times the level in approved semaglutide products. Research-use-only wording does not make a product safe for people. See are peptides legal and research use vs human use.

What to watch next

  1. The submission itself, which is firmer news than a target.
  2. Whether FDA accepts the filing, which review path it names, and how the BLA question is settled.
  3. Full TRIUMPH-2 and TRIUMPH-3 papers: dropout rates, tolerability while doses rise, glucose and cardiovascular outcomes, serious adverse events and subgroup differences.

See an approved comparator in retatrutide vs tirzepatide, the retatrutide research page, or ask Pulse.

Frequently asked questions

Did Lilly push the filing back because Phase 3 failed?

No. Lilly said both TRIUMPH-2 and TRIUMPH-3 achieved their primary goals, and that it is still completing the manufacturing documentation.

Is retatrutide FDA approved?

No. It remained investigational as of September 2026, with a U.S. submission planned for Q1 2027.

Would a Q1 2027 submission mean approval in 2027?

Not automatically. FDA must accept the application, finish its review and judge whether the data and manufacturing justify approval. It may ask for more information or decline.

What is CMC?

Chemistry, Manufacturing, and Controls: the record of how a medicine is produced, tested, kept stable and made reliably at scale.

Can a clinic compound retatrutide during review?

No compounded or research product should be described as approved retatrutide or as the same as Lilly’s trial drug. The medicine is unapproved, and there is no approved version to replicate.

References

  1. Lilly: retatrutide TRIUMPH-1 Phase 3 results, May 21, 2026 — lilly.com
  2. Lilly: TRIUMPH-2 and TRIUMPH-3 results and Q1 2027 submission plan, July 23, 2026 — lilly.com
  3. Lilly: TRIUMPH-4 results, Dec 11, 2025 — lilly.com
  4. TGA: counterfeit retatrutide product testing — tga.gov.au
  5. FDA: concerns with unapproved GLP-1 drugs — fda.gov

Go deeper on Signal IQ

Dosing & protocolRetatrutide

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading